Pfizer, Moderna among vaccine makers to watch in 2023, Barron’s says

Until the pandemic hit, Wall Street largely ignored the vaccine market, but this year will show there’s more to jabs than fighting COVID-19, Josh Nathan-Kazis writes in this week’s edition of Barron’s. In 2023, drug companies will introduce the first vaccines for respiratory syncytial virus — known as RSV — and could roll out the first flu vaccine based on messenger RNA, or mRNA. It will also be a significant year for COVID-19 shots, which are expected to make their debut on the commercial market, the author notes. 2023 should be a big year for vaccine makers; Pfizer (PFE), Moderna (MRNA), GSK (GSK), and Sanofi (SNY) are the to watch, the publication adds. Reference Link